Groupama Asset Management Boosts Thermo Fisher Scientific Holdings

Institutional investor increases stake in medical research company by nearly 59% in Q3 2025

Mar. 19, 2026 at 9:37am

Got story updates? Submit your updates here. ›

Groupama Asset Management, a French asset management firm, grew its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 58.9% during the third quarter of 2025, according to a recent SEC filing. The firm now owns 245,016 shares of the medical research company's stock, valued at around $118.8 million.

Why it matters

Thermo Fisher Scientific is a major player in the life sciences and medical research industries, providing analytical instruments, reagents, and other critical equipment and supplies to laboratories worldwide. Institutional investors closely monitor the company's performance, and changes in their holdings can signal broader market trends or shifts in investor sentiment.

The details

Groupama Asset Management's increased stake in Thermo Fisher Scientific represents a significant vote of confidence in the company's prospects. The firm purchased an additional 90,854 shares during the third quarter, bringing its total position to 245,016 shares, or approximately 0.07% of the company's outstanding stock.

  • Groupama Asset Management filed its Q3 2025 Form 13F with the SEC on March 19, 2026, disclosing the increased stake in Thermo Fisher Scientific.

The players

Groupama Asset Management

A French asset management firm that oversees investments in a variety of sectors, including life sciences and healthcare.

Thermo Fisher Scientific Inc.

A global provider of scientific instrumentation, reagents, software, and services that support research, clinical, and industrial laboratories.

Got photos? Submit your photos here. ›

The takeaway

Groupama Asset Management's increased stake in Thermo Fisher Scientific suggests continued confidence in the company's long-term growth prospects within the medical research and life sciences industries. This move aligns with broader trends of institutional investors seeking exposure to companies that provide essential tools and technologies to the scientific community.